

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Substitute for form 1449/PTO			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			
Sheet	1	of	2
		Attorney Docket Number 062331-5002-US	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/AMG/	1	Arvanitis et al. "Conditional transgenic models define how MYC initiates and maintains tumorigenesis" Seminars in Cancer Biology, 16 (2006): 313-317.	
	2	Cheng et al. "Relationship between LAPT M4B gene polymorphism and susceptibility of colorectal and esophageal cancers" Ann. Oncol., 2008, 19(3): 527-532.	
	3	Deng et al. "Relationship between LAPT M4B gene polymorphism and susceptibility of lung cancer", Beijing Da Xue Xue Bao, 2005, 37(3):302-305. Abstract.	
	4	Hanahan et al. "The hallmarks of cancer." Cell, 2000, 100(1): 57-70.	
	5	He et al. "Effects of the novel gene, LAPT M4B, highly expression in hepatocellular carcinoma on cell proliferation and tumorigenesis of NIH3T3 cells" J. Peking University (Health Sciences), 2003, 35(4): 348-352.	
	6	Liu et al. "Structure analysis and expressions of a novel tetraspanmembrane protein, lysosome-associated protein transmembrane 4 beta associated with hepatocellular carcinoma", World J Gastroenterol. 2004, 10(11): 1555-1559.	
	7	Liu et al. "Relationship between LAPT M4B gene polymorphism and susceptibility of gastric cancer" Ann. Oncol., 2007, 18(2): 311-316.	
	8	Pelengaris et al. "c-MYC: more than just a matter of life and death", Nat. Rev. Cancer, 2002, 2(10):764-776.	
	9	Peng et al. "Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma.", World J. Gastroenterol. 2005. 11 (18): 2704-2708.	
/AMG/	10	Shachaf et al. "MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer" Nature, 2004, 431(7012): 1112-1117.	

Examiner Signature	/Anne M. Gussoow/	Date Considered	01/21/2009
--------------------	-------------------	-----------------	------------

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Application is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

<b>Application Number</b>	10/540,539
<b>Filing Date</b>	October 4, 2006
<b>First Named Inventor</b>	Rouli Zhou
<b>Art Unit</b>	1643
<b>Examiner Name</b>	Anne Gussow
<b>Attorney Docket Number</b>	062331-5002-US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/AMG/	11	Yang et al. "LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma", Oncology Reports, 2008, July, accepted.	
	12	Zhou et al. "Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma". European Journal of Cancer, 43 (4): 809 – 815.	
	13	Zhou et al. "Expression of LAPTM4B-35: A novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma", Cancer Letter, 264(2): 209-217.	
	14	Zhou et al. "LAPTM4B, a hepatocellular carcinoma-associated novel proto-oncogene", Falk Symposium 150, Berlin, 2005.10, Abstract p.121 and poster prized by the conference.	
	15	Zhou et al. "LAPTM4B, A Novel Cancer Target (II)", The 3rd International Congress of Cancer progression, Baltimore, 2006, Abstract, p.102-103 and poster.	
	16	Zhou et al. "LAPTM4B plays critical roles in tumorigenesis of human cells by activating several signaling pathways". The 5th Asian-Pacific Organization for Cell Biology Congress, 2006, Beijing. Abstract, p.77, oral presentation.	
/AMG/	17	Zhou et al. "LAPTM4B activates signaling pathways of cell survival and proliferation as an organizing platform for signal molecules and plays critical roles in malignant transformation". The 9th Conference of Chinese Society for Cell Biology, Abstract p.52, 2007, Guangzhou, oral presentation.	

Examiner Signature	/Anne M. Gussow/	Date Considered	01/21/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2